AMLo Biosciences’ Post

In case you missed our recent announcement about our prognostic #melanoma biomarker: our prognostic #melanoma biomarker #AMBLor successfully received its #UKCA mark and is now available to healthcare professionals. AMBLor accurately identifies early-stage melanomas at low risk of progression. bit.ly/479VHJK   In the US, AMBLor testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. #dermatology #dermatopathology #histopathology #histology #oncology #skincancer #cancerresearch #biomarkers #healthinvestment

Fuel your in vitro skin models with our unique human iPSC-derived sebocytes, and build robust and relevant tools for your research into skin disorders linked to hyper- and hypo-seborrhea, and for pharmacology, toxicology and drug discovery, including 3D skin reconstruction. Key highlights of our iPSC-derived sebocytes include: -Display the typical epithelial morphology of primary sebocytes with heterogeneity in cell size due to lipid accumulation. -Express the key sebocyte markers MUC1 (MUCIN 1) and KRT7 (KERATIN 7) -Exhibit functional response to testosterone and linoleic acid To find out why we are the only choice for iPSC-derived sebocytes, click here: https://lnkd.in/ew_jTiUK Looking to build human-relevant skin models for research or drug discovery? Let's have a conversation! operations@axolbio.com #iPSCs #StemCells #Sebocytes #Dermatology #SkinModels

The latest #psoriasis slide decks are now available on the #IMIDForum! Explore new insights and data to enhance your practice with the top research in #dermatology: [LINK] This month’s Literature Highlights are now available on the Immune-Mediated Inflammatory Disease Forum! November’s single slide summary includes a study by Huang, et al., where they aimed to identify predictors and construct a predictive model for time to relapse following withdrawal from biologics. Find out more about this publication, and more about #psoriasis on the IMID Forum today. 🔗https://ow.ly/z06850UhCMV

Clexio Biosciences is pleased to announce that we have reached 50% enrollment in our CLE-400 Phase 2 proof-of-concept study, in subjects suffering from chronic pruritus associated with Notalgia Paresthetica.   The study is a randomized, double-blind, vehicle-controlled multi-center study, enrolling in the US, assessing the efficacy and safety of our CLE-400 topical gel.   Notalgia Paresthetica is a type of sensory neuropathy associated with chronic itch in the upper back. Patients’ quality of life, sleep, and mood can be negatively impacted by this condition. To-date, there are no approved treatments for this condition.   CLE-400 is a topical formulation containing a potent α2-adrenergic agonist, a non-opioid and non-steroid. CLE-400 is an investigational drug and is currently not approved for commercial distribution. For more information on CLE-400: https://lnkd.in/dQ-GJkwE #clexio #clinicaltrials #notalgiaparesthetica #itch #dermatology #neuropathy

Always exciting, the Spring #AAD meeting gives us opportunities network and to reconnect with friends and colleagues. As a forum for information exchange, the meeting is overwhelming with multiple simultaneous sessions and massive plenaries. For me, the most interesting sessions are the Late-Breaking Research Sessions. Seeing the effect of new pathways – Brunton’s tyrosine kinase inhibition for #HidradenitisSuppurativa, increases our understanding of the drivers of #HS. It is always exciting to see further development of new compounds – ESK-001, JNJ-77242113, delgocitinib, ritlecitinib, prepocitinib, povorcitinib, B-VEC, ICP-332, amlitelimab, lutikizumab, sonelokimab, nemolizumab, deuruxoltinib, benvitimod, SHR0302. Keep up the good work. #AAD2024 #dermatology #clinicalresearch #drugdevelopment

🌟 Exciting News from Symmetron! 🌟 📢 The 2023 update of the EULAR recommendations for psoriatic arthritis (PsA) management have arrived with new guidelines, including 7 overarching principles and 11 recommendations driven by developments in drug safety and efficacy. A special shoutout to our Symmetron colleagues for authoring the network meta-analysis (NMA) cited as providing the key comparative efficacy evidence for biologic and targeted synthetic disease modifying anti-rheumatic drugs (DMARDs). 👏 Join us in celebrating these advancements for better patient outcomes. 📈 🔗 Follow the link in the comments to dive into the details! 🔗 #HEOR #Research #Dermatology

#Psoriasis affects 125 million people worldwide. It’s more than a skin condition—it can impact every aspect of life, bringing both physical discomfort and emotional strain. 🤝 This #WorldPsoriasisDay, we’re stepping up to support those living with plaque psoriasis, which accounts for 80-90% of cases. 📍 At Scinai Immunotherapeutics Ltd., we are dedicated to transforming psoriasis care. Our drug development program focuses on a targeted therapy specifically for mild to moderate plaque psoriasis. Leveraging single-domain antibodies (sdAbs), including our anti-IL-17A/F sdAb, we are advancing a locally administered biologic that combines high potency and convenience with a safer profile than current treatments. 👉 Join us in raising awareness and supporting those affected by psoriasis. Together, we can make a difference for millions. 🌐 Visit Scinai.com to learn more #InnovativeResearch #Healthcare #Biotechnology #Dermatology #WorldPsoriasisDay24

PEGASUS’ was a randomised double blind placebo controlled #trial of a Bruton Tyrosine Kinase Inhibitor (BTKI) in pemphigus. Rilzabrutinib is a reversible BTKI. In this global study, new onset and recalcitrant pemphigus vulgaris (PV-90%) and foliaceus (PF-10%) patients were treated with medium doses of prednisone (o.5 mg/kg/d) and randomised to rilza vs placebo. The primary outcome was the proportion of PV patients in Complete remission (no lesions- PDAI zero for at least 8 weeks) on minimal therapy at week 37. In this original protocol, p<0.05 but the trial was completed during the pandemic and FDA mandated excluding patients with remote visits and that minimal therapy be increased to 10mg/d pred; with these restrictions, p>0.05. Murrell et al https://lnkd.in/dNg8iNrU #derm #RCT #pemphigus #rilzabrutinib #clinicaltrial #phase3 #outcomes #PDAI #safety #international #dermatology #principiabio #sanofi #BTKI The PEGASUS study was conducted from January 8, 2019 through October 8, 2021, in 19 countries (Argentina, Australia, Brazil, Bulgaria, Canada, Croatia, France, Germany, Greece, Israel, Italy, Poland, Serbia, Spain, Taiwan, Turkey, Ukraine, United Kingdom, and United States).

We recently we had the great pleasure of meeting with some of the world’s leading experts in the fields of #Dermatology and #AtopicDermatitis, to discuss clinical development plans for the lead candidate in our pipeline of disease-modifying #Therapies for chronic #Autoimmune and #InflammatoryDiseases. SYX-5219, which will advance into the clinic for the treatment of atopic dermatitis, targets a critical enzyme regulating cell #Metabolism called pyruvate kinase M2 (PKM2) – a novel therapeutic target with the potential to rebalance the #ImmuneSystem, normalize immune cell function and drive sustained disease remission.    As we finalise our development plans for this candidate, it’s vital that we collaborate with, and learn from, those who are expert in the field and those who are treating patients today. A huge thank you to everyone who shared their time, knowledge, insights and real-world experiences – invaluable to us in ensuring our #Science can continue to progress at pace for the benefit of patients.   Find out more about the latest progress within Sitryx’s proprietary pipeline: https://lnkd.in/eS8FGNRx